Redcare Pharmacy Future Growth
Future criteria checks 4/6
Redcare Pharmacy is forecast to grow earnings and revenue by 62.6% and 16% per annum respectively. EPS is expected to grow by 0.5% per annum. Return on equity is forecast to be 17.6% in 3 years.
Key information
62.6%
Earnings growth rate
0.5%
EPS growth rate
Consumer Retailing earnings growth | 13.2% |
Revenue growth rate | 16.0% |
Future return on equity | 17.6% |
Analyst coverage | Good |
Last updated | 10 Jan 2025 |
Recent future growth updates
Recent updates
Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt
Nov 11Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?
Apr 21Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?
Apr 07Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues
Mar 25Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt
Feb 13Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S
Dec 24Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?
Dec 06Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Sep 07Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching
Aug 02Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price
Jul 17Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher
May 28Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt
May 11We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt
Jan 10Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?
Sep 25Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?
Jun 08Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?
Feb 28Here's Why Shop Apotheke Europe (ETR:SAE) Has A Meaningful Debt Burden
Aug 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 4,181 | 113 | N/A | N/A | 4 |
12/31/2026 | 3,547 | 55 | 52 | 126 | 12 |
12/31/2025 | 2,943 | -4 | -7 | 69 | 12 |
12/31/2024 | 2,379 | -39 | -29 | 48 | 12 |
9/30/2024 | 2,227 | -25 | -11 | 31 | N/A |
6/30/2024 | 2,128 | -9 | -8 | 33 | N/A |
3/31/2024 | 1,987 | -10 | 0 | 38 | N/A |
12/31/2023 | 1,799 | -12 | 23 | 61 | N/A |
9/30/2023 | 1,595 | -16 | -2 | 40 | N/A |
6/30/2023 | 1,404 | -45 | -13 | 33 | N/A |
3/31/2023 | 1,272 | -65 | -59 | -9 | N/A |
12/31/2022 | 1,204 | -78 | -83 | -29 | N/A |
9/30/2022 | 1,165 | -110 | -68 | -16 | N/A |
6/30/2022 | 1,118 | -105 | -48 | 1 | N/A |
3/31/2022 | 1,081 | -91 | -40 | 6 | N/A |
12/31/2021 | 1,060 | -74 | -32 | 12 | N/A |
9/30/2021 | 1,037 | -39 | -14 | 35 | N/A |
6/30/2021 | 1,038 | -29 | -28 | 27 | N/A |
3/31/2021 | 1,020 | -18 | -17 | 35 | N/A |
12/31/2020 | 968 | -17 | -36 | 18 | N/A |
9/30/2020 | 895 | -15 | -56 | -19 | N/A |
6/30/2020 | 827 | -20 | -43 | -19 | N/A |
3/31/2020 | 758 | -27 | -38 | -16 | N/A |
12/31/2019 | 701 | -36 | -45 | -31 | N/A |
9/30/2019 | 660 | -41 | -25 | -11 | N/A |
6/30/2019 | 621 | -40 | -22 | -10 | N/A |
3/31/2019 | 584 | -40 | -39 | -26 | N/A |
12/31/2018 | 540 | -34 | -26 | -15 | N/A |
9/30/2018 | 481 | -31 | -40 | -31 | N/A |
6/30/2018 | 415 | -28 | N/A | -24 | N/A |
3/31/2018 | 351 | -24 | N/A | -17 | N/A |
12/31/2017 | 284 | -21 | N/A | -23 | N/A |
9/30/2017 | 244 | -22 | N/A | -11 | N/A |
6/30/2017 | 222 | -20 | N/A | -16 | N/A |
3/31/2017 | 200 | -20 | N/A | -14 | N/A |
12/31/2016 | 177 | -18 | N/A | -17 | N/A |
9/30/2016 | 159 | -13 | N/A | -5 | N/A |
6/30/2016 | 147 | -13 | N/A | -5 | N/A |
3/31/2016 | 136 | -12 | N/A | -7 | N/A |
12/31/2015 | 126 | -11 | N/A | -9 | N/A |
12/31/2014 | 85 | -5 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RDC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: RDC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RDC is expected to become profitable in the next 3 years.
Revenue vs Market: RDC's revenue (16% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: RDC's revenue (16% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RDC's Return on Equity is forecast to be low in 3 years time (17.6%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/14 03:30 |
End of Day Share Price | 2025/01/14 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Redcare Pharmacy NV is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Volker Bosse | Baader Helvea Equity Research |
Gerhard Schwarz | Baader Helvea Equity Research |
Alvira Rao | Barclays |